特宝生物：9月26日召开董事会会议

Group 1 - The core point of the article is that Tebao Biological announced a board meeting to discuss the cancellation of unvested restricted stock options from the 2024 incentive plan [1] - Tebao Biological's revenue composition for the year 2024 is reported to be 99.73% from biological agents and 0.27% from other businesses [1] - As of the report, Tebao Biological has a market capitalization of 33.4 billion yuan [1] Group 2 - The article mentions a significant growth in a new type of insurance product, which has seen a 33-fold increase over five years, attracting over 30 insurance companies to enter the market [1]